WEST PALM BEACH, Fla., April 25, 2011 /PRNewswire/ — The
ophthalmic therapeutics company Xcovery Vision announced today that
Sheridan G. Snyder, OBE, Chairman and CEO, and Dr. Ken Mandell,
President and COO, will be speaking at The Association for Research
in Vision and Ophthalmology (ARVO) Annual Meeting in Fort
Lauderdale Florida, May 1-5, 2011. Mr. Snyder’s talk
Perspective of a Serial Entrepreneur recounts his repeated
success as founder of multiple biotech companies that include
Genzyme, Upstate Biotechnology, Biotage and Molecular MD.
Dr. Ken Mandell will present preclinical study results with
Xcovery Vision’s novel angiogenesis inhibitor XV-615
currently being developed for age-related macular degeneration
(AMD). This study Intravitreally Delivered VEGFR/PDGFR Inhibitor
XV-615: Safety Assessment in Rabbits was conducted in
collaboration with Massachusetts-based ocular therapeutics company
EyeGate Pharma (www.eyegatepharma.com).
About the Ophthalmology Drug Market
Ophthalmic drugs constitute a prominent segment of the global
pharmaceutical market. From 2003 to 2008, sales of ophthalmic
medications nearly doubled from $2.9 billion to $5.2 billion in the
U.S. alone. Globally, ophthalmic pharmaceuticals are growing at
annual rate of 6% and expected to reach $33 Billion by 2023. This
growth has been attributed in part to the aging population in which
the prevalence of diseases such as age-related macular degeneration
(AMD), diabetic retinopathy, glaucoma and dry eye syndrome are
steadily rising. There is therefore an increasing need for
novel therapies to provide treatment to this growing patient
population.
About Age-related Macular Degeneration (AMD)
AMD is the leading cause of blindness in patients over 55 in the
United States and affects 50 million people worldwide. More
than 10 million people in U.S. are currently affe
‘/>”/>
